Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
Data ReadoutpositiveFoundayoPositive
AI Analysis
Summary
Lilly's oral GLP-1 Foundayo (orforglipron) demonstrated cardiovascular safety and efficacy in the ACHIEVE-4 type 2 diabetes study, meeting its primary non-inferiority objective versus insulin glargine with significant reductions in MACE and cardiovascular death risk.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
ACHIEVE-4 study met primary non-inferiority endpoint versus insulin glargine, with 16% lower MACE-4 risk and 23% lower MACE-3 risk. Pre-planned analyses showed 53% lower cardiovascular death risk and 57% reduction in another cardiovascular measure.
Importance:8/10
Sentiment:
0.85
GLP-1 agonistoral formulationcardiovascular safetyweight lossA1C reductionMACE endpointnon-inferiority
Related Companies
Read the original article
Published by PR Newswire Pharma on September 30, 2026 10:00 PM